Nucleic Acid Therapeutics for Neurological Diseases

Overview

Journal Neurotherapeutics

Specialty Neurology

Date 2019 May 1

PMID 31037650

Citations 11

Authors

Jonathan K Watts

Robert H Brown

Anastasia Khvorova

Affiliations

Soon will be listed here.

Citing Articles

Nose-to-Brain (N2B) Delivery: An Alternative Route for the Delivery of Biologics in the Management and Treatment of Central Nervous System Disorders.

Patharapankal E, Ajiboye A, Mattern C, Trivedi V Pharmaceutics. 2024; 16(1).

PMID: 38258077 PMC: 10818989. DOI: 10.3390/pharmaceutics16010066.

Small molecule regulators of microRNAs identified by high-throughput screen coupled with high-throughput sequencing.

Nguyen L, Wei Z, Silva M, Barberan-Soler S, Zhang J, Rabinovsky R Nat Commun. 2023; 14(1):7575.

PMID: 37989753 PMC: 10663445. DOI: 10.1038/s41467-023-43293-0.

Intranasal delivery: An attractive route for the administration of nucleic acid based therapeutics for CNS disorders.

Shah P, Lalan M, Barve K Front Pharmacol. 2022; 13:974666.

PMID: 36110526 PMC: 9469903. DOI: 10.3389/fphar.2022.974666.

Beyond GalNAc! Drug delivery systems comprising complex oligosaccharides for targeted use of nucleic acid therapeutics.

OSullivan J, Munoz-Munoz J, Turnbull G, Sim N, Penny S, Moschos S RSC Adv. 2022; 12(32):20432-20446.

PMID: 35919168 PMC: 9281799. DOI: 10.1039/d2ra01999j.

Cerebral Organoids and Antisense Oligonucleotide Therapeutics: Challenges and Opportunities.

Lange J, Zhou H, McTague A Front Mol Neurosci. 2022; 15:941528.

PMID: 35836547 PMC: 9274522. DOI: 10.3389/fnmol.2022.941528.

References

Khvorova A, Watts J . The chemical evolution of oligonucleotide therapies of clinical utility. Nat Biotechnol. 2017; 35(3):238-248. PMC: 5517098. DOI: 10.1038/nbt.3765. View

Nakamori M, Junn E, Mochizuki H, Mouradian M . Nucleic Acid-Based Therapeutics for Parkinson's Disease. Neurotherapeutics. 2019; 16(2):287-298. PMC: 6554378. DOI: 10.1007/s13311-019-00714-7. View

Aartsma-Rus A . FDA Approval of Nusinersen for Spinal Muscular Atrophy Makes 2016 the Year of Splice Modulating Oligonucleotides. Nucleic Acid Ther. 2017; 27(2):67-69. DOI: 10.1089/nat.2017.0665. View

Hastings M, Jones T . Antisense Oligonucleotides for the Treatment of Inner Ear Dysfunction. Neurotherapeutics. 2019; 16(2):348-359. PMC: 6554385. DOI: 10.1007/s13311-019-00729-0. View

Raal F, Santos R, Blom D, Marais A, Charng M, Cromwell W . Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010; 375(9719):998-1006. DOI: 10.1016/S0140-6736(10)60284-X. View

Krichevsky A, Uhlmann E . Oligonucleotide Therapeutics as a New Class of Drugs for Malignant Brain Tumors: Targeting mRNAs, Regulatory RNAs, Mutations, Combinations, and Beyond. Neurotherapeutics. 2019; 16(2):319-347. PMC: 6554258. DOI: 10.1007/s13311-018-00702-3. View

Buijsen R, Toonen L, Gardiner S, van Roon-Mom W . Genetics, Mechanisms, and Therapeutic Progress in Polyglutamine Spinocerebellar Ataxias. Neurotherapeutics. 2019; 16(2):263-286. PMC: 6554265. DOI: 10.1007/s13311-018-00696-y. View

Benson M, Waddington-Cruz M, Berk J, Polydefkis M, Dyck P, Wang A . Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018; 379(1):22-31. DOI: 10.1056/NEJMoa1716793. View

Chiriboga C, Swoboda K, Darras B, Iannaccone S, Montes J, De Vivo D . Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy. Neurology. 2016; 86(10):890-7. PMC: 4782111. DOI: 10.1212/WNL.0000000000002445. View

10.

Greenfield A, Hauser S . Nucleic Acid-Based Therapeutics Relevant to Neuroimmune Conditions. Neurotherapeutics. 2019; 16(2):314-318. PMC: 6554460. DOI: 10.1007/s13311-019-00740-5. View

11.

Cohen J . Informational drugs: a new concept in pharmacology. Antisense Res Dev. 1991; 1(2):191-3. DOI: 10.1089/ard.1991.1.191. View

12.

Zain R, Smith C . Targeted Oligonucleotides for Treating Neurodegenerative Tandem Repeat Diseases. Neurotherapeutics. 2019; 16(2):248-262. PMC: 6554256. DOI: 10.1007/s13311-019-00712-9. View

13.

Henninger N, Mayasi Y . Nucleic Acid Therapies for Ischemic Stroke. Neurotherapeutics. 2019; 16(2):299-313. PMC: 6554367. DOI: 10.1007/s13311-019-00710-x. View

14.

Corey D . Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy. Nat Neurosci. 2017; 20(4):497-499. DOI: 10.1038/nn.4508. View

15.

Adams D, Gonzalez-Duarte A, ORiordan W, Yang C, Ueda M, Kristen A . Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018; 379(1):11-21. DOI: 10.1056/NEJMoa1716153. View